From the UK to China for Medical Care: NHS Waits, Private Costs, Insurance Pathways, and a Decision Framework

Reading time: 18 minutes

In September 2024, the NHS England elective waiting list reached 7.5 million people — roughly one in seven English adults sat on a queue for non-emergency treatment [1]. The NHS’s own 18-week referral-to-treatment target was met for only 58% of patients; the 62-day urgent cancer pathway target was met for only 62% [2]. A woman with a suspected breast lump waits, on average, 6 to 12 weeks from GP referral to first specialist appointment, with the full diagnostic-and-decision journey routinely exceeding 100 days.

Private healthcare in the UK exists in parallel, but in 2024 a single private hip replacement averaged £17,000 to £20,000 — including admission, anaesthesia, and implant [16]. Bupa UK, AXA Health, Vitality and other domestic policies cover many middle-income families, but the small print bites: waiting periods, pre-existing-condition exclusions, annual caps, and a near-blanket exclusion on planned overseas treatment mean many policyholders never actually use what they’re paying for.

This is why more UK residents are starting to ask about international medical pathways — and, increasingly, about China. This article will help you decide: does your situation actually warrant looking at China? If it does, what’s the pathway, what does it cost, will your insurance work, and what’s the process from end to end?

1. Where the NHS actually bottlenecks

The principle behind the NHS is “allocate by medical need, not by ability to pay.” That principle remains sound. But when demand vastly exceeds supply, the allocation mechanism becomes queuing. NHS England’s 2024 statistics show the real cadence of that queue [1][2]:

Procedure	NHS median wait	Share meeting target
Hip replacement	18-30 weeks (some regions 40+ weeks)	18-week target — 58% met
Knee replacement	18-30 weeks	Same
Cataract surgery	14-20 weeks	—
Spine surgery (non-emergent)	40+ weeks	—
MRI (non-urgent)	6-12 weeks	—
CT (non-urgent)	4-8 weeks	—
Specialist consult (oncology)	2-6 weeks (urgent pathway)	Cancer 62-day target — 62% met
Specialist consult (mental health)	8-24 weeks	—
Endoscopy (gastroscopy / colonoscopy)	6-12 weeks	—

What NHS coverage actually includes (and excludes) [3][4]:

Covered: GP visits, specialist consults (by GP referral), inpatient care, surgery, A&E, most diagnostic imaging, most prescription drugs (England NHS prescription charge £9.90 per item; free for over-65s, pregnant women, diabetes, etc.).
Not covered or partially covered: dental beyond basic NHS dentistry, vision correction surgery, PET-CT outside clear oncology indications, most private clinic services, planned overseas care.
Key NHS constraint: you cannot pay out-of-pocket to jump the queue inside an NHS hospital. “Patient Choice” lets you choose between NHS providers, but you remain in the public queue. Paying privately means stepping out of the NHS into a parallel system priced by the market.

What UK private care actually looks like:

Major private hospital groups: Spire Healthcare [16], HCA Healthcare UK (including The Princess Grace, The Wellington, London Bridge) [17], Nuffield Health, Circle Health Group (incorporating BMI), The London Clinic [18], Cromwell Hospital.
Private MRI / CT / PET-CT self-pay is accessible in London, Manchester, Birmingham, Edinburgh and other large cities at £600-£2,800.
The “NHS top-up” phenomenon: many UK patients use the NHS for diagnosis and initial assessment, then pay privately to avoid the wait for surgery. This route remains expensive: a private hip replacement at £17K-£20K is the norm.
Private consultants are mostly NHS consultants moonlighting. Clinical skill is the same as NHS; the gap is wait time and service experience. In effect, paying privately is paying to skip the queue with the same doctor.

2. Situations where “look at China” is a reasonable decision

Not every medical need is suited to crossing borders. Below are the situations where, in our experience, UK residents have a real case for considering China.

Situations that suit a China pathway

🟢 Wait-time-sensitive

Hip and knee replacement, spine decompression, cataract — long NHS waits (18 to 40+ weeks), mature procedures, you can fly home shortly after.
IVF evaluation — NHS coverage is a “postcode lottery” with wide regional variation; private single cycle £8,000-£12,000.
Non-emergent surgery where pain or function loss is materially affecting daily life and a 6-12 month wait isn’t workable.

🟢 Diagnostic-acceleration cases

PET-CT for cancer staging, recurrence monitoring, or surveillance — bookable in 3-7 days in China versus 4-8 weeks via the NHS.
PET-MR, high-field MRI, endoscopy — completed as a 3-5 day package.
Pathology slide re-reading — can be done remotely; no travel needed.

🟢 Second opinion and plan confirmation

An NHS diagnosis and treatment plan exists, but you want it pressure-tested.
Oncology, haematology, complex surgical decisions warranting multidisciplinary review.
NHS consultants generally welcome second opinions; an international second opinion (including from China) is a defensible fit.

🟢 Advanced therapies where eligibility is already pointing to China

CAR-T cell therapy — six NMPA-approved products in China at roughly 1/4 to 1/3 of the UK private route (which can run £300K+ self-pay with 6-12 month wait).
Proton and heavy-ion therapy — the UK has two NHS proton centres (UCLH London and The Christie, Manchester) plus historically one private facility (Rutherford, since restructured). China’s Shanghai Proton and Heavy Ion Center (SPHIC, public) and the Heyou Proton & Heavy Ion Center inside Heyou Pinnacle Medical Center (private, Foshan-Shunde) are among the very few centres on the Chinese mainland equipped with both proton and heavy-ion capability [13]; some indications approved in China are not yet routinely available in the UK.
Certain biologics — broader access, lower pricing.

🟢 Premium executive physicals and early-cancer screening

Comprehensive packages completed in 3-5 days.
Imaging quality comparable to top UK private centres.
English-speaking International Medical Departments (no language barrier for UK residents).

Situations that don’t suit China

🔴 Emergencies and critical illness — heart attack, stroke, major trauma, uncontrolled infection, severe bleeding. Handle locally. Crossing borders is itself the medical risk.

🔴 Unstable patients who can’t fly long-haul — fit-to-fly must be assessed by your existing treating physician (NHS or private), not by us.

🔴 Expecting “a miracle cure” — if NHS oncology has called your case untreatable, “China must have something” is usually disappointment in waiting.

🔴 Price as the sole driver — Turkey or India may be cheaper for some procedures. China’s edge is the combination of clinical depth, price, and speed. Lowest price is not the headline.

3. Two systems in China — and a bridge that runs only one way

This is the part UK patients most often misunderstand. We need to be explicit, because misunderstanding it costs you money.

Chinese hospitals fall into two distinct systems:

Public Tier-3A hospitals

Tier-3A (三级甲等) is the top rank in China’s hospital classification — equivalent to a UK “teaching hospital” or academic medical centre.
Examples: Peking Union Medical College Hospital (Beijing), Beijing Tiantan Hospital, Shanghai Ruijin Hospital, Fudan-Zhongshan, Sun Yat-sen Memorial in Guangzhou, and many others.
Strengths: concentration of senior specialists, very high surgical volumes, can handle the most complex cases, costs are 30-50% of private international.
Weaknesses: limited English in general wards (you’ll need an interpreter and accompaniment), queue logic built around domestic patient flow, inpatient wards utilitarian rather than hotel-grade.
The International Medical Department (IMD) is the dedicated bilingual channel inside top Tier-3A hospitals — Peking Union, West China, Ruijin, Huashan, Zhongshan and others all run IMDs designed for international patients.

Private international hospitals — more complex than you’d think from abroad

Examples: United Family Healthcare (Beijing/Shanghai/Guangzhou), Shanghai Jiahui International Hospital, Heyou Pinnacle Medical Center (Foshan-Shunde, founded by the founder of Midea Group with combined system investment of over RMB 10 billion), Concord Medical’s Guangzhou Concord Cancer Center (proton therapy operational from late 2024), and others.
Strengths go beyond service: fluent English, comprehensive insurance direct billing, hotel-style rooms, on-time appointments, transparent international workflow. But a small number of leading private hospitals also run equipment that matches or surpasses most public hospitals — Heyou Pinnacle’s affiliated Heyou Proton & Heavy Ion Center is led by Professor Lu Jiade, who established the clinical technology system at Shanghai SPHIC [13], making it one of the few proton-and-heavy-ion-capable centres on the Chinese mainland. Guangzhou Concord Cancer Center became South China’s first operating private proton therapy centre in late 2024.
Physician composition isn’t simple either: the overwhelming majority of China’s top specialists remain in the public Tier-3A system, but in recent years a smaller cohort of senior physicians have moved part-time or full-time into private hospitals, drawn by compensation, research autonomy, and lower administrative load. Heyou Pinnacle is the clearest case in point — beyond Lu Jiade, the group has attracted Li Baomin (national pioneer in neurointervention, 20,000+ stent placement and embolisation cases), Su Fengxi (Honorary President of Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital, over 10,000 breast cancer surgeries, national leader in breast-conserving surgery), and other senior specialists. The blanket assumption “private equals weaker doctors” is too simple. What matters is who the lead surgeon is, what their actual surgical volume in that procedure is over the last 12 months, and the team behind them.
The real complexity: Chinese private hospitals are a hybrid system where the bulk of authority still sits in public Tier-3A, but local capability is iterating quickly in pockets. Which private hospital can perform which procedure at what level, who can take over post-op care, whether your insurance is in-network — these are case-by-case, hospital-by-hospital, surgeon-by-surgeon decisions. That’s the work MedCareInChina actually does.
Shared weakness: the most complex, specialty-defining procedures (top-tier neurosurgery, complex cardiac, oncology mega-surgery, transplant) — public Tier-3A remains the primary route. Private coverage is expanding rapidly but unevenly.

⚠️ The one-way bridge — the rule you can’t afford to get wrong

UK patients often assume they can “do diagnostics at private and surgery at public.” That path does not work in China.

The actual rule is asymmetric:

✅ Public → Private works. A diagnosis, imaging report, or prescription issued by a public Tier-3A hospital is recognised by private international hospitals. Private hospitals will continue prescribing, do follow-up, and conduct monitoring on the basis of the public hospital’s work.
❌ Private → Public does not. A private hospital’s consultation, imaging interpretation, or treatment plan is generally not accepted by a public Tier-3A as the basis for surgery or admission. If you want public treatment, the public hospital will require its own physicians to evaluate from scratch — frequently including repeat imaging and pathology review.

The reason: public Tier-3A is the higher-ranked tier in the Chinese medical hierarchy, and the downstream (private) accepts the upstream (public), but not vice versa.

What this means for your decision:

Complex cases (specialty-defining: top oncology, complex cardiac, complex neuro, transplant): stay in the public Tier-3A system end-to-end — from initial evaluation through surgery through follow-up. Same team, same chart, most accurate post-op judgment. If you bridge to private for follow-up of a complex case, any concerning finding will route you back to public anyway.
Routine cases (outpatient, imaging, executive physical, IVF, general specialty, dermatology, ophthalmology): stay in private international end-to-end. No reason to involve public.
The Public → Private follow-up bridge: appropriate for stable patients who’ve completed public treatment and need routine medication management or monitoring, especially those for whom English and service experience matter. Not appropriate for complex post-operative tracking.
❌ What not to do: assume you can run diagnostics at private and “save money by getting the surgery at public.” The result is paying for the workup twice.

4. Real cost comparison (GBP/USD, all at 1 USD = 6.5 RMB)

The table below combines NHS published data, UK private hospital price lists, and public price ranges from Chinese public and private international hospitals. All figures are ranges, not commitments. The final invoice depends on actual treatment, length of stay, complications, and insurance review.

Procedure	NHS (wait + coverage)	UK Private Self-Pay	China Public IMD + Accompaniment	China Private International
Hip replacement	Wait 18-30 weeks, NHS covers	£17,000-£22,000	USD $8,000-$12,000	USD $15,000-$22,000
Knee replacement	Wait 18-30 weeks, NHS covers	£17,000-£22,000	USD $8,000-$12,000	USD $15,000-$22,000
Spine fusion (single level)	Wait 40+ weeks	£25,000-£35,000	USD $12,000-$18,000	USD $25,000-$35,000
Cataract (standard IOL, one eye)	Wait 14-20 weeks	£2,500-£4,500	USD $800-$1,500	USD $2,500-$4,000
Cataract (premium multifocal IOL)	Not covered	£4,500-£7,500	USD $2,000-$3,500	USD $4,500-$7,000
PET-CT	Partly covered (oncology)	£1,800-£2,800	USD $1,500-$2,500	USD $2,500-$3,500
MRI	Wait 6-12 weeks, NHS covers	£600-£1,200	USD $200-$500	USD $500-$900
Comprehensive checkup (incl. PET-CT)	Not covered	£3,500-£8,000	USD $2,500-$4,500	USD $5,500-$9,500
Upper + lower endoscopy (with anaesthesia)	Wait 6-12 weeks	£2,200-£3,800	USD $700-$1,500	USD $2,000-$3,500
IVF, single cycle	Coverage varies by CCG	£8,000-£12,000	USD $5,000-$8,000	USD $10,000-$16,000
CAR-T cell therapy [12][21]	NHS covers DLBCL etc., 6-12 month wait	£350K-£500K (private)	USD $160K-$220K (all-inclusive)	Not performed at private
Proton / heavy-ion therapy [13]	NHS at UCLH + The Christie only, strict criteria	£80K-£200K (overseas private)	USD $30K-$50K (SPHIC, public; proton + heavy-ion)	Heyou Pinnacle (proton + heavy-ion); Guangzhou Concord (proton); case-by-case

Notes on what the table doesn’t show:

UK private consultants are mostly NHS consultants moonlighting — the clinical skill is the same as NHS; what you’re paying for is wait-time elimination and service experience. Not a different doctor.
The NHS’s “free” coverage has a cost denominated in time. A patient waiting 30 weeks for a hip replacement and living on painkillers for seven months pays a real cost that isn’t money.
UK private and Chinese private international prices are already close in some procedures. China private international is 30-50% cheaper than UK private — but the larger gap is wait time: 1-2 weeks in China versus 2-6 weeks at UK private.

5. Do UK insurance plans actually work in China?

The honest answer: it depends on which plan you hold and whether your insurer has a direct-billing contract with your target hospital.

International medical insurance networks in China (2025 status)

The following are sold in the UK and have substantial direct-billing networks in China [14]:

Bupa Global [6] — UK-headquartered. Expanded in 2025 to 3,600 designated hospitals across 300 cities, covering both public IMDs and private international. Important: Bupa Global is not Bupa UK — Bupa UK domestic policies do not cover planned overseas treatment.
Cigna Global [5] — global network of 1.65M facilities; Shanghai operations centre; China direct billing covers both public and private.
AXA Global Healthcare [9] — AXA’s international product (distinct from AXA Health UK / PPP). Via its Prosper Health partnership, covers approximately 1,350 Tier-3A public hospitals (including PUMCH, Sun Yat-sen, Huashan) plus major private internationals.
Allianz Worldwide Care (sold in the UK as Allianz Care) [7] — 280+ public IMD and private international hospitals in China.
MSH International [8] — 500+ hospitals across 20+ cities in China, covering both public and private.
William Russell [10] — UK-based international product.
April International [11] — French-origin, available via UK brokers.

Plans that generally won’t work for planned care in China (UK domestic)

Bupa UK (Bupa By You / Bupa Select) — domestic plan, does not cover planned overseas surgery.
AXA Health UK (PPP Healthcare) — same.
Vitality Health, AVIVA Health, WPA (Western Provident Association) — all UK domestic; do not cover planned overseas.
Travel insurance — covers sudden illness and accidents only, not planned treatment.
NHS out-of-country coverage — only emergency; the historical EHIC/GHIC scheme has been substantially reduced post-Brexit.

Direct billing vs reimbursement

Direct billing: the insurer pays the hospital directly; you cover only your deductible and copay. The widely repeated claim that “only private international hospitals support direct billing” is out of date — leading public Tier-3A IMDs now run extensive direct-billing networks. Concrete examples [14]:

Public IMD	Direct-billing insurers
Shanghai Huashan IMC	30+ direct billing contracts, ~100 actual partnerships; insurance business accounts for over 50% of revenue
Shanghai Ruijin IMD	20+ direct-billing insurers (system in place since 1998)
Peking Union (PUMCH) IMS	Maintains a full “Cooperative Commercial Insurance Roster” including major international insurers
Sun Yat-sen 1st Affiliated Hospital Nansha IMC	15 commercial insurers (opened 2023)

Private international hospital	Direct-billing insurers
Shanghai Jiahui International Hospital	~60 global insurers (broadest in East China)
Shanghai ParkwayHealth / SIMC	50+ direct billing; SIMC 60+ global partners
United Family Healthcare (Beijing/Shanghai/Guangzhou/Shenzhen/Boao)	22 international insurers
Heyou Pinnacle Medical Center (Foshan-Shunde)	Supports international commercial insurance direct billing; designated institution under the GBA “HK/Macao Drug & Device Access” policy

The decision criterion isn’t public vs private — it’s whether your specific insurer has an active direct-billing contract with the specific hospital you’re targeting. That has to be confirmed in writing before you travel.

Reimbursement (when direct billing isn’t available): you pay out of pocket, then claim back home. Almost all international policies accept this, but you’ll need:

English-language medical records, itemised bills, and the Chinese tax invoice (Fapiao).
Pre-authorisation filed with your insurer in advance (typically 24-48 hours processing).
Treatment falling within your policy scope.
A 4-12 week processing window.

What we can do, and what we don’t

⚠️ MedCareInChina is not an insurance company. We do not negotiate with your insurer on your behalf, and we do not advance insurance funds.

What we can do:

Help you confirm with your insurer whether your policy covers your planned treatment and whether your target hospital is in-network.
Help you prepare the pre-authorisation package your insurer requires (treatment plan, cost estimate, specialist letter).
Coordinate direct-billing communication and GOP (Guarantee of Payment) application between the Chinese hospital (public IMD or private international) and your insurer.
After discharge, organise your English-language medical records, bills, and payment receipts for your reimbursement claim back home.

What we don’t do:

Make insurance decisions for you.
Promise your insurer will approve.
Hold or pass through insurance funds (all medical fees go directly from you to the hospital).

6. The five steps of going from the UK to China for care

Total elapsed time from your first email to your return flight is roughly 6-12 weeks (not counting treatment itself).

Step 1 · Free Pathway Scan (1-2 business days)

Send us a short email. Tell us:

Your current condition or diagnostic direction
Your UK region and a rough travel window
Whether you carry international medical insurance
A description of records you have on hand (no need to send files at this stage; description is enough)

We reply within 1-2 business days with:

Whether your situation is worth continuing to prepare for China
A recommended next step: remote consultation, direct travel, or stay in the UK
A short list of additional records to gather

This step is free, with no commitment. If we judge your situation isn’t right for China, we’ll tell you directly. We don’t push referrals.

Step 2 · Remote Expert / MDT Consultation (5-10 business days, paid)

If Step 1 confirms it’s worth continuing, the next step is remote consultation:

Single Expert: USD $800 flat — includes records organisation, Chinese case brief, specialist matching, video consultation, and a bilingual PDF report.
MDT (Multidisciplinary Team): USD $1,000 per specialist (a typical MDT = 3 specialists = USD $3,000) — suited for complex oncology, cross-specialty decisions.
Your records get translated and organised into a Chinese-language case brief.
We match a suitable Chinese specialist (public Tier-3A or private international, based on your case).
A video consultation is scheduled (you may attend or not).
A bilingual English-Chinese consultation report is delivered within 5-10 business days.

The deliverable is a formal medical opinion: the Chinese specialist’s view on your case, whether travel to China is recommended, candidate hospitals/cities/physicians, expected duration and cost range, and a next-step checklist.

You can take this report back to your NHS GP or private consultant for discussion. You can also stop here and not proceed further — our service can end at this step.

Step 3 · S2 Medical Visa (2-4 weeks)

For UK passport holders coming to China for medical reasons:

S2 visa [15][19]: medical treatment ≤6 months. The typical patient visa. Requires a Chinese-hospital-issued invitation letter or acceptance letter.
S1 visa [15][19]: medical treatment >6 months (long oncology protocols, etc.), allows accompanying family. Requires a long-term treatment confirmation from the hospital.
L visa (tourist): technically possible for a short single consultation, but not recommended — many hospital international departments don’t accept an L visa as a basis for sustained treatment.

⚠️ MedCareInChina does not process visas. We can coordinate the hospital to issue the invitation letter, but the visa application itself must be filed by you at the Chinese Embassy in London or via CVASC visa centres in London, Edinburgh, or Manchester [20].

The invitation letter typically takes 5-10 business days to obtain. Standard visa processing at CVASC is 4-7 business days. Expedited service is available at additional cost.

Step 4 · In-China Accompanied Care (during treatment)

Once you’re in China, we provide in-China accompanied care:

Airport pickup to hotel and hospital.
Appointment coordination: confirming your exams, surgery, and admission schedule.
Medical interpretation and accompaniment: bilingual support for exams, consultations, and pre/post-op communication.
Payment coordination: walking with you to the hospital cashier (the hospital Fapiao is issued directly to you).
Insurance documentation support: organising GOP, pre-authorisation, and discharge files for your reimbursement claim.
Discharge documents: English-language discharge summary, medication list, follow-up plan, imaging files (DICOM disc or cloud).
Hand-off back home: assistance coordinating with your NHS GP or private consultant.

Typical durations in China: hip/knee replacement 5-7 days inpatient + 1-2 weeks recovery observation = 2-3 weeks total; cataract 1 outpatient day + 1-2 days observation = 3-4 days; comprehensive checkup 3-5 days.

Fee structure:

Consultation fee (paid at Step 2): paid to MedCareInChina.
Accompanied care service fee: based on your itinerary length and complexity, stated in writing before you sign.
Hospital and physician fees: paid directly to the hospital. MedCareInChina does not handle medical funds.
Hotel, flights, transport: you arrange and pay directly. We don’t book these.

Step 5 · Remote follow-up after returning home

Back in the UK:

Your Chinese attending physician schedules remote follow-up at agreed time points (video).
We continue to coordinate communication between the Chinese hospital and your NHS GP or private consultant.
If your insurer requires additional documentation, we continue providing English-language materials.
If you face a medical emergency, seek local UK emergency care immediately — do not try to reach the Chinese hospital for emergency handling.

7. When you shouldn’t consider China (the honest filter)

You’re currently admitted in an NHS hospital and unstable — flying poses higher risk than any benefit.
You don’t yet have baseline diagnosis, imaging, or medication records — we have nothing to evaluate and can’t prepare a remote consultation.
You’re hoping “China must have something” for late-stage disease that NHS oncology has called untreatable — managing that expectation isn’t something we can do, and the result is usually disappointment.
Cost is your only driver — Turkey or India may be more cost-optimal for your specific case.
You can’t accommodate a 6-12 week process — that’s the realistic time budget. If you can’t, don’t start.
Your insurance excludes overseas care and self-pay is genuinely outside your budget — re-read Section 4. If even the low end of the range is unmanageable, don’t start.

8. Frequently asked, honestly answered

Q: Can I have my NHS GP or private consultant be involved from the start?
Yes — we encourage it. Consultation reports are bilingual by default specifically so you can hand them to your UK clinician. We don’t replace your treating team; the goal is to add a viewpoint.

Q: Can the consultation report be used to support Bupa Global / AXA reimbursement?
Depends on your policy. The Chinese-language case brief, Chinese specialist opinion, and English report can serve as second-opinion evidence. UK domestic plans (Bupa UK, AXA Health UK, Vitality, AVIVA) generally don’t reimburse planned overseas care. International insurers (Bupa Global, Cigna Global, AXA Global Healthcare, etc.) vary — confirm with the insurer directly.

Q: If something goes wrong during surgery, who’s responsible?
The Chinese hospital. MedCareInChina is not a medical provider, does not make medical decisions, and is not responsible for medical outcomes. All clinical judgments, surgical plans, and prescribing decisions are made by the Chinese hospital and physician you select, and they bear responsibility for outcomes. This is set out in our Terms of Service and Medical Disclaimer [22].

Q: Can I request a specific hospital or physician?
You can express a preference; we don’t guarantee we can match it. Final matching depends on the physician’s schedule, their willingness to take international patients, and whether your case actually fits their subspecialty. If your preferred match isn’t appropriate, we’ll suggest an equivalent alternative.

Q: Do I need a family member with me in China?
Not always. Outpatient and minor procedures (cataract, imaging, checkups) work fine solo. Major surgery and inpatient stays are strongly recommended with a family member (the S2 visa supports a separate accompanying-family application). If a family member isn’t possible, our accompanied-care service covers most practical needs.

Q: How soon after surgery can I fly back to the UK?
Depends on the procedure. Cataract — fly day 2. Joint replacement — typically 2-3 weeks observation plus a pre-flight medical assessment. Spine surgery — 3-4 weeks. Major cancer surgery — 4-6 weeks. Fit-to-fly assessment is required and is issued by the treating physician — we don’t issue Fit-to-fly.

Q: What if I arrive in China and the treatment turns out not to fit?
This is exactly why we insist on a remote consultation before travel. If the consultation concludes that China isn’t right for your case, we’ll tell you and explicitly recommend against coming. In the rare situation where, on arrival, additional Chinese-side workup uncovers something that changes the plan, the Chinese hospital and you make the new decision jointly. We facilitate communication — we don’t make medical decisions for you.

Q: Should I choose public or private in China? How do I decide?
This isn’t your choice to make blind — it’s a match based on your case. Complex specialty-defining cases (oncology, complex cardiac, neuro, transplant) — public Tier-3A is essentially the only option. Routine outpatient, imaging, checkup, general specialty — private international can handle the whole thing. In the middle (mid-complexity surgery, needing English plus insurance direct billing plus a degree of specialty depth) — that’s the genuine gray zone that requires case-by-case, physician-by-physician evaluation. That’s the work we do: matching your specific case to a city, hospital, and physician, with a defensible reason — not pointing you at a generic category of hospital.

9. Next step — send us your case

📧 hello@medcareinchina.com

Subject: Pathway Scan from UK

In the body, tell us:

Your current condition or diagnostic direction (one or two sentences)
Your UK region and rough travel window
Whether you carry international medical insurance (insurer name is enough — no policy number needed)
The state of your medical records (records, imaging, medication list — describe; don’t send files yet)

We respond within 1-2 UK business days with a free written assessment.

This step is always free. No payment, no commitment, no follow-up marketing emails. If after reading the reply you decide it’s not for you, that’s the end of it. If you want to continue, we discuss the next step then.

Sources

[1] NHS England · Consultant-led Referral to Treatment Waiting Times Data 2024 — NHS waiting list, 18-week target performance, specialty waiting times. https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/

[2] NHS England · Cancer Waiting Times Statistics — 62-day urgent referral cancer pathway target performance. https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/

[3] NHS · What the NHS Covers — Official NHS coverage scope. https://www.nhs.uk/nhs-services/

[4] NHS Constitution for England — Statutory document on NHS patient rights and commitments, including wait-time targets. https://www.gov.uk/government/publications/the-nhs-constitution-for-england

[5] Cigna Global · International Health Insurance — China direct billing network. https://www.cignaglobal.com/

[6] Bupa Global · Find a Provider — Bupa Global Premier policyholder network and direct-billing arrangements in China (2025 expansion to 3,600 designated hospitals across 300 cities). https://www.bupaglobal.com/en/customers/find-a-provider

[7] Allianz Care · International Medical Insurance — China provider network (280+ public IMD and private international hospitals). https://www.allianzcare.com/

[8] MSH International — China direct billing network (500+ hospitals across 20+ cities). https://www.msh-intl.com/

[9] AXA Global Healthcare — AXA’s international product (distinct from AXA Health UK domestic). Via Prosper Health partnership covers approximately 1,350 Tier-3A hospitals. https://www.axaglobalhealthcare.com/

[10] William Russell · International Health Insurance — UK-origin international medical insurer. https://www.william-russell.com/

[11] April International — French-origin, available via UK brokers. https://www.april-international.com/

[12] MedCareInChina · CAR-T Cell Therapy in China — China CAR-T pricing comparison and underlying data (NMPA approvals, FDA approvals, Drugs.com U.S. list pricing). https://medcareinchina.com/car-t-cell-therapy-in-china-six-approved-products-top-centers-pricing-and-comparison-with-western-centers/

[13] Shanghai Proton and Heavy Ion Center (SPHIC) + Heyou Pinnacle Medical Center (Foshan-Shunde) + Guangzhou Concord Cancer Center — Reference for proton and heavy-ion therapy options in China. Heyou Pinnacle’s Heyou Proton & Heavy Ion Center is directed by Professor Lu Jiade, who established the clinical technology system at SPHIC; Guangzhou Concord Cancer Center (Concord Medical Group) launched proton therapy operations in December 2024. https://medcareinchina.com/proton-and-heavy-ion-therapy-in-china-sphic-process-indications-and-comparison-with-us-japan-and-europe/

[14] MedCareInChina · International Medical Insurance and China Hospital Direct Billing — Reference article including the public IMD direct-billing roster cited above (Huashan ~100 partnerships, Ruijin 20+, PUMCH cooperative insurance roster, Sun Yat-sen Nansha 15) and private hospital networks (Jiahui ~60, ParkwayHealth 50+, United Family 22, Heyou Pinnacle GBA designation). https://medcareinchina.com/international-medical-insurance-and-china-hospital-direct-billing-a-complete-guide-to-coverage-workflow-and-pitfalls/

[15] MedCareInChina · Complete Guide to China Medical Visa (S1/S2) — Reference article on S1 and S2 medical visa requirements. https://medcareinchina.com/complete-guide-to-china-medical-visa-s1-s2-the-first-step-for-international-patients/

[16] Spire Healthcare — Major UK private hospital group; public reference for hip/knee replacement self-pay pricing. https://www.spirehealthcare.com/

[17] HCA Healthcare UK — Includes The Princess Grace, The Wellington, London Bridge and other top-tier UK private hospitals. https://www.hcahealthcare.co.uk/

[18] The London Clinic — London-based independent private hospital; public price reference. https://www.thelondonclinic.co.uk/

[19] Embassy of the People’s Republic of China in the UK · Visa Information — Official source for S1 and S2 medical visa rules for UK applicants. http://gb.china-embassy.gov.cn/eng/

[20] Chinese Visa Application Service Centre (CVASC) · UK — Visa processing centres serving UK residents (London, Edinburgh, Manchester). https://www.visaforchina.cn/

[21] U.S. CAR-T list pricing (Yescarta, Kymriah, Carvykti) — Drugs.com cross-referenced for U.S. comparison pricing used in Section 4 table. https://www.drugs.com/medical-answers/cost-yescarta-3342568/

[22] MedCareInChina · Service & Refund Policy / Medical Disclaimer / Privacy Policy — Full service boundary documentation. Service & Refund Policy · Medical Disclaimer · Privacy Policy

Last updated 2026-05-29. All USD/RMB conversions calculated at 1 USD = 6.5 RMB; actual exchange rate at settlement applies. All medical decisions remain between you and your treating physician. MedCareInChina provides patient navigation services; it is not a medical provider, does not diagnose, does not prescribe, and does not guarantee treatment outcomes.

— MedCareInChina Editorial Team